Further to the Heads-of-Terms announced on 9 August 2021, Microsaic has confirmed its signing of an agreement (‘the Agreement’) with Jiangsu Henzhihe Technologies Co. Ltd.
(‘HZH’), to provide services including product manufacturing, integration and operation of a service centre in support of distribution and prospective OEM partnerships in China. Remaining on track to secure a China medical device licence in 2022, the Group is now developing a local capability with Chinese partners for the mass production of its miniaturised mass spectrometry (‘MS’) instruments, with a view to maximising available margin through reduced costs while broadening its marketing reach.
Targeting annual sales of up to 100 units for each therapeutic drug monitoring sector over the next two to three years, with further opportunity in other analytical areas, HZH has confirmed it can meet the prospective demand requirements for both China and the rest of the world.
We would draw your attention to the various disclaimers in the document both at the beginning and at the end of the note. Retail clients (as defined by the rules of the FCA) must not rely on the research document. In particular you should note that the research document is a non-independent marketing communication. The analyst who has prepared the research is aware that TPI provides research to Microsaic Systems plc and DeepVerge plc. Accordingly the research has not been prepared in accordance with legal requirements designed to promote the independence of investment research and is not subject to any prohibitions on dealing ahead of its dissemination.
The information in the document is published solely for information purposes and is not to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments. The material contained in the document is general information intended for recipients who understand the risks associated with equity investment in smaller companies. It does not constitute a personal recommendation as defined by the FCA or take into account the particular investment objectives, financial situation or needs of individual investors nor provide any indication as to whether an investment, a course of action or the associated risks are suitable for the recipient.
Copyright © 2021 Turner Pope Investments (TPI) Limited, all rights reserved.